SAR 264565

Drug Profile

SAR 264565

Alternative Names: SAR264565

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi Aventis Deutschland GmbH
  • Class Antiplatelets; Fab fragments; Glycoproteins
  • Mechanism of Action Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 18 May 2017 Preclinical trials in Thrombosis in Germany (parenteral)
  • 18 May 2017 Pharmacodynamics data from preclinical development in Thrombosis released by Sanofi-Aventis Deutschland GmbH
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top